Novartis, Molecular Partners Report Positive Data for Covid-19 Treatment Ensovibep

- Advertisement -


By Ed Frankl
- Advertisement -

Novartis AG and Molecular Partners AG on Monday reported positive topline data from their antiviral COVID-19 treatment Ensovibep, and will seek rapid regulatory authorization globally.

- Advertisement -

Results of a Phase 2 study of 407 patients receiving a single intravenous dose of Ensovibep showed a 78% reduction in COVID-19-related hospitalizations or emergency-room visits and clinical recovery compared to a placebo. Time showed improvement, Novartis said.

The Basel-based drugmaker said Ensovibap is continuing treatment against the types of anxiety identified so far, including Omicron.

- Advertisement -

Novartis also said it would exercise its option and pay 150 million Swiss francs ($163.3 million) to in-license Ensovibep from Molecular Partners and accelerate manufacturing scale-up.

It plans to first obtain accelerated regulatory authorization globally through the US Food and Drug Administration’s Emergency Use Authorization.

Novartis said that if approved, Ensovibep would be the first multi-specific antiviral molecule for the treatment of Covid-19.

Write to Ed Frankl at [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox